Turnstone Biologics
Driving innate and adaptive tumor immunity to provide benefit to cancer patients underserved by current treatments.
Launch date
Employees
Market cap
€13.9m
Enterprise valuation
(€41m) (Public information from Sep 2024)
Share price
$0.675 TSBX
San Francisco California (HQ)
Financials
Estimates*
USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Revenues | 101m | 73.3m | 19.3m | - | - | - |
% growth | - | (28 %) | (74 %) | - | - | - |
EBITDA | 34.4m | (27.7m) | (56.2m) | (86.4m) | (92.8m) | - |
% EBITDA margin | 34 % | (38 %) | (291 %) | - | - | - |
Profit | 33.3m | (30.8m) | (55.2m) | (83.2m) | (88.7m) | (111m) |
% profit margin | 33 % | (42 %) | (286 %) | - | - | - |
EV / revenue | - | - | 3.0x | - | - | - |
EV / EBITDA | - | - | -1.1x | -0.2x | -0.2x | - |
R&D budget | 54.8m | 86.7m | 60.5m | - | - | - |
R&D % of revenue | 54 % | 118 % | 313 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$11.3m | Series A | ||
$41.4m | Series B | ||
N/A | N/A | - | |
N/A | N/A | - | |
$80.0m | Series D | ||
* | N/A | $80.0m | IPO |
Total Funding | €121m |
Recent News about Turnstone Biologics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Turnstone Biologics
EditACQUISITION by Turnstone Biologics Jan 2021